DXB
DIMERIX LIMITED
$0.2200
0.00%
Market cap
$132M
Turnover
$81,479
Last price
$0.2200
Day change
0.00%
Announcements
20
Range, past year
Open 0.525 · Low 0.155 · Now 0.220 · High 0.785
Open DXB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
DXB momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
22/100
Wyckoff phase
Accumulation7d
Trend stage
Neutral
1 Day
+0.0%
1 Week
-4.3%
1 Month
-8.3%
1 Year
-57.7%
RSI
36
Avg daily range
6.2%
DIMERIX LIMITED scores 22 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 7 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -32.3%
- High volatility (ATR 6.2%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
DXB announcements
Recent price-sensitive releases.
- 2026-10-05 First Patient Reaches Four Years in DMX-200 Clinical Program Progress Report
- 2026-09-23 Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility Progress Report | Debt Facility
- 2026-09-14 Dimerix DMX-652 Granted Mexican Composition of Matter Patent Progress Report
- 2026-09-04 Dimerix Secures A$34 Million Non-Dilutive Funding Facility Trading Halt Lifted | Debt Facility
- 2026-09-02 Trading Halt Trading Halt
- 2026-08-27 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-20 Dimerix Receives US$10M Upfront Payment from Everest Progress Report
More Health Care stocks
Most traded in the same sector.